Ebtehal El-Demerdash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ebtehal El-Demerdash has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Eman M. Mantawy
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
14 shared publicationsSara A. Wahdan
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Egypt
12 shared publicationsWesam M. El-Bakly
Department of Pharmacology
9 shared publicationsDoaa A. Elsherbiny
Pharmacology & Toxicology Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
7 shared publicationsAhmed Esmat
Department of Pharmacology & Toxicology, Faculty of Pharmacy Ain Shams University Cairo Egypt
6 shared publicationsSamar S. Azab
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
6 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7847
Kaiso Is a Novel TAZ-Interaction Partner That Promotes Hepatic Stellate Cell Activation and Regulates the Downstream lncRNA HIF1A-AS3
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are key regulators of hepatic stellate cell (HSC) activation and liver fibrosis. While the canonical YAP/TAZ-TEAD axis is well-characterized, non-canonical interaction partners and downstream long non-coding RNAs (lncRNAs) that orchestrate fibrogenic programs in HSCs remain undefined. Using BioID and next-generation sequencing (NGS) in LX-2 cells, we identified YAP/TAZ-interactomes and YAP/TAZ-regulated lncRNAs. BioID results and proximity ligation assay (PLA) identified the transcription factor Kaiso as a TAZ interaction partner. Functionally, Kaiso knockdown suppressed key aspects of HSC activation in LX-2 cells. We next integrated our NGS results from YAP/TAZ-knockdown in LX-2 cells with publicly available Kaiso ChIP-seq data. This identified HIF1A-AS3 as a common downstream lncRNA. ChIP-qPCR confirmed direct binding of Kaiso to the HIF1A-AS3 promoter. Furthermore, HIF1A-AS3 silencing mirrored the functional effects of Kaiso knockdown. Global proteomic profiling following knockdown of TAZ, Kaiso, or HIF1A-AS3 revealed a network of commonly regulated proteins enriched for pathways central to HSC activation. In conclusion, we establish Kaiso as a novel TAZ interaction partner and identify HIF1A-AS3 as a shared downstream target of TAZ and Kaiso, suggesting a potential profibrotic regulatory network that promotes HSC activation and may represent a therapeutic target for liver fibrosis.
- 2 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7847
Open AccessKaiso Is a Novel TAZ-Interaction Partner That Promotes Hepatic Stellate Cell Activation and Regulates the Downstream lncRNA HIF1A-AS3
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are key regulators of hepatic stellate cell (HSC) activation and liver fibrosis. While the canonical YAP/TAZ-TEAD axis is well-characterized, non-canonical interaction partners and downstream long non-coding RNAs (lncRNAs) that orchestrate fibrogenic programs in HSCs remain undefined. Using BioID and next-generation sequencing (NGS) in LX-2 cells, we identified YAP/TAZ-interactomes and YAP/TAZ-regulated lncRNAs. BioID results and proximity ligation assay (PLA) identified the transcription factor Kaiso as a TAZ interaction partner. Functionally, Kaiso knockdown suppressed key aspects of HSC activation in LX-2 cells. We next integrated our NGS results from YAP/TAZ-knockdown in LX-2 cells with publicly available Kaiso ChIP-seq data. This identified HIF1A-AS3 as a common downstream lncRNA. ChIP-qPCR confirmed direct binding of Kaiso to the HIF1A-AS3 promoter. Furthermore, HIF1A-AS3 silencing mirrored the functional effects of Kaiso knockdown. Global proteomic profiling following knockdown of TAZ, Kaiso, or HIF1A-AS3 revealed a network of commonly regulated proteins enriched for pathways central to HSC activation. In conclusion, we establish Kaiso as a novel TAZ interaction partner and identify HIF1A-AS3 as a shared downstream target of TAZ and Kaiso, suggesting a potential profibrotic regulatory network that promotes HSC activation and may represent a therapeutic target for liver fibrosis.
- Open Access
- 8 June 2026
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 38 (1) , 19
Radiosensitizing effect of astaxanthin on radiation–induced cytotoxicity in breast cancer cells
Background: Radiotherapy (RT) is a primary treatment for cancer, including breast cancer, but its effectiveness is limited by severe side effects. Radiosensitization using natural products can enhance efficacy while reducing radiation doses. Astaxanthin (AST), a natural carotenoid with antioxidant properties, requires further investigation for its role in cancer therapy. Especially in many previous studies, AST found to has prooxidant effect in cancer cells reverse its antioxidant effect in normal cells. Methods: This study explored AST’s potential to enhance the cytotoxic effects of ionizing radiation (IRR) against MCF7 breast cancer cells and the underlying mechanisms. Cytotoxicity, apoptosis induction, anti-metastatic activity, and cell cycle distribution were analyzed in response to IRR with and without AST. Results: IRR alone showed limited cytotoxicity, whereas addition of AST significantly enhanced IRR’s effects, reducing IC 50 by ten folds in combination treatment. AST increased apoptosis markers (caspase-3 and BAX/BCL2 ratio) by 16% and 67.8%, respectively. It also decreased proliferation index and S-phase ratio by 43.24% and 42.6%, respectively. AST further reduced metastatic markers MMP2 and MMP9 by 25% and 33.8%, respectively, in combination therapy. Additionally, AST exhibited a pro-oxidant effect, elevating MDA and H₂O₂ levels by 16.9% and 18.9%, respectively. It also caused cell cycle arrest at the S and G2/M phases, making cells more susceptible to IRR. Conclusion: These findings confirm AST’s radiosensitizing effect via apoptosis induction, cell cycle disruption, and anti-metastatic activity, supporting its potential in enhancing radiotherapy efficacy for breast cancer cells. Further research is warranted to explore its application in cancer treatment.
- 8 June 2026
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 38 (1) , 19
Open AccessRadiosensitizing effect of astaxanthin on radiation–induced cytotoxicity in breast cancer cells
Background: Radiotherapy (RT) is a primary treatment for cancer, including breast cancer, but its effectiveness is limited by severe side effects. Radiosensitization using natural products can enhance efficacy while reducing radiation doses. Astaxanthin (AST), a natural carotenoid with antioxidant properties, requires further investigation for its role in cancer therapy. Especially in many previous studies, AST found to has prooxidant effect in cancer cells reverse its antioxidant effect in normal cells. Methods: This study explored AST’s potential to enhance the cytotoxic effects of ionizing radiation (IRR) against MCF7 breast cancer cells and the underlying mechanisms. Cytotoxicity, apoptosis induction, anti-metastatic activity, and cell cycle distribution were analyzed in response to IRR with and without AST. Results: IRR alone showed limited cytotoxicity, whereas addition of AST significantly enhanced IRR’s effects, reducing IC 50 by ten folds in combination treatment. AST increased apoptosis markers (caspase-3 and BAX/BCL2 ratio) by 16% and 67.8%, respectively. It also decreased proliferation index and S-phase ratio by 43.24% and 42.6%, respectively. AST further reduced metastatic markers MMP2 and MMP9 by 25% and 33.8%, respectively, in combination therapy. Additionally, AST exhibited a pro-oxidant effect, elevating MDA and H₂O₂ levels by 16.9% and 18.9%, respectively. It also caused cell cycle arrest at the S and G2/M phases, making cells more susceptible to IRR. Conclusion: These findings confirm AST’s radiosensitizing effect via apoptosis induction, cell cycle disruption, and anti-metastatic activity, supporting its potential in enhancing radiotherapy efficacy for breast cancer cells. Further research is warranted to explore its application in cancer treatment.
- Open Access
- 12 May 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (6) , 3157-3176
Dapagliflozin targets the crosstalk between apoptosis, autophagy, and Hedgehog signaling pathways through AMPK activation in the adjuvant-induced arthritic rat model
Rheumatoid arthritis is a long-term autoimmune disorder, causes joint capsule, cartilage, and bone damage. Dapagliflozin, a novel antidiabetic drug, demonstrated promising effects against different disorders. Herein, we aimed to detect the dose-dependent antiarthritic impact of dapagliflozin alone and in combination with methotrexate standard treatment. Complete Freund’s adjuvant-induced arthritic rats were treated with three doses of dapagliflozin (1, 5, or 10 mg/kg/day, p.o.) for 3 weeks, in which 10 mg dose showed eminent anti-arthritic effects according to gait score, paw diameter, arthritic index (AI), morphological and histological results. To reveal dapagliflozin mechanism, locomotor, biochemical, and histological measures were assessed in dapagliflozin (10 mg/kg/day) and/or methotrexate (0.75 mg/kg/week, i.p.)-treated arthritic rats. Radiography and histology confirmed the prominent anti-arthritic effect of dapagliflozin via reduced RF, MMP-1, and MMP-3, and improved gait score, ankle diameter, and AI. Anti-inflammatory impact was confirmed by the downregulation of TNF-α, IL-1β, IL-6, and NF-κb p65 expression. Upregulation of autophagy was detected through; Beclin-1, ULK-1, and ATG-7, in dapagliflozin treated arthritic rats. Furtherly, dapagliflozin stimulated apoptotic activity, by boosting articular levels of CASP-3, CASP-9, cartilage gene expression of p53, and Bax/Bcl2 ratio. Interestingly, dapagliflozin upregulates p-AMPK/t-AMPK articular activity. Additionally, dapagliflozin inhibited the Hedgehog signaling pathway, through the downregulation of cartilage Shh, ptch1, Smo, and Gli-1 expression. Dapagliflozin/methotrexate combination therapy exhibited greater anti-arthritic benefits compared to methotrexate alone. These data highlight dapagliflozin as an anti-rheumatic drug, either alone or with methotrexate.
- 12 May 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (6) , 3157-3176
Open AccessDapagliflozin targets the crosstalk between apoptosis, autophagy, and Hedgehog signaling pathways through AMPK activation in the adjuvant-induced arthritic rat model
Rheumatoid arthritis is a long-term autoimmune disorder, causes joint capsule, cartilage, and bone damage. Dapagliflozin, a novel antidiabetic drug, demonstrated promising effects against different disorders. Herein, we aimed to detect the dose-dependent antiarthritic impact of dapagliflozin alone and in combination with methotrexate standard treatment. Complete Freund’s adjuvant-induced arthritic rats were treated with three doses of dapagliflozin (1, 5, or 10 mg/kg/day, p.o.) for 3 weeks, in which 10 mg dose showed eminent anti-arthritic effects according to gait score, paw diameter, arthritic index (AI), morphological and histological results. To reveal dapagliflozin mechanism, locomotor, biochemical, and histological measures were assessed in dapagliflozin (10 mg/kg/day) and/or methotrexate (0.75 mg/kg/week, i.p.)-treated arthritic rats. Radiography and histology confirmed the prominent anti-arthritic effect of dapagliflozin via reduced RF, MMP-1, and MMP-3, and improved gait score, ankle diameter, and AI. Anti-inflammatory impact was confirmed by the downregulation of TNF-α, IL-1β, IL-6, and NF-κb p65 expression. Upregulation of autophagy was detected through; Beclin-1, ULK-1, and ATG-7, in dapagliflozin treated arthritic rats. Furtherly, dapagliflozin stimulated apoptotic activity, by boosting articular levels of CASP-3, CASP-9, cartilage gene expression of p53, and Bax/Bcl2 ratio. Interestingly, dapagliflozin upregulates p-AMPK/t-AMPK articular activity. Additionally, dapagliflozin inhibited the Hedgehog signaling pathway, through the downregulation of cartilage Shh, ptch1, Smo, and Gli-1 expression. Dapagliflozin/methotrexate combination therapy exhibited greater anti-arthritic benefits compared to methotrexate alone. These data highlight dapagliflozin as an anti-rheumatic drug, either alone or with methotrexate.
- Open Access
- 12 April 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 1-14
Can vildagliptin protect against radiation-induced premature ovarian failure? Insights into the AMPK and AKT signaling pathways
Background: Among the detrimental side effects caused by radiotherapy in young females is the ovarian damage, eventually causing premature ovarian failure (POF). While many signaling pathways contribute to the pathogenesis of POF, to date no sufficient data exist on the AMPK and AKT signaling pathways in irradiated ovaries. Both AMPK and AKT play crucial roles in the process of folliculogenesis. Vildagliptin (vilda) is a dipeptidyl peptidase-4 inhibitor with modulatory effect on both AMPK and AKT. Therefore, our study aimed to investigate the biochemical changes that occur in the AMPK/AKT signaling pathway, and the effect of co-administration of vildagliptin in radiation-induced POF. Methods: Female Sprague-dawley rats were randomly divided into four groups: control, radiation, radiation + vilda, or vilda alone groups. Vilda was administered orally once/day, and on the 10th day of the experiment, radiation and radiation + vilda group rats were subjected to 3.2 Gy of whole-body gamma irradiation. Behavioral activity was assessed on the 13th day of the experiment. On day 14 of the experiment, all rats were euthanized. Serum samples were collected, and ovaries were dissected for histological and biochemical analyses. Results: Irradiation of female rats resulted in increased locomotor hyperactivity, impaired memory, and ovarian damage as evidenced by the marked histopathological deterioration. Additionally, irradiation led to a significant decrease in body weight gain, gonadosomatic index, and serum estradiol level. Further, it caused a significant increase in serum AMH, phosphorylated AMPK, phosphorylated AKT, cytoplasmic Nrf2 expression and phosphorylated CREB levels. Co-administration of vilda exhibited neuroprotective effects, preserved the ovarian histological architecture but failed to preserve the primordial follicle pool in irradiated rats. Conclusion: In conclusion, AMPK/AKT signaling pathway is upregulated in radiation-induced POF. It possibly contributes to POF pathogenesis by accelerating the activation of primordial follicles, hence leading to their premature depletion. Coadministration of vilda can protect the ovaries and temporarily preserve its endocrine function; however, it does not sustain the ovarian reproductive capacity due to the early depletion of the pool of primordial follicles. Women undergoing radiotherapy should be cautious with the use of AKT-activating drugs.
- 12 April 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 1-14
Open AccessCan vildagliptin protect against radiation-induced premature ovarian failure? Insights into the AMPK and AKT signaling pathways
Background: Among the detrimental side effects caused by radiotherapy in young females is the ovarian damage, eventually causing premature ovarian failure (POF). While many signaling pathways contribute to the pathogenesis of POF, to date no sufficient data exist on the AMPK and AKT signaling pathways in irradiated ovaries. Both AMPK and AKT play crucial roles in the process of folliculogenesis. Vildagliptin (vilda) is a dipeptidyl peptidase-4 inhibitor with modulatory effect on both AMPK and AKT. Therefore, our study aimed to investigate the biochemical changes that occur in the AMPK/AKT signaling pathway, and the effect of co-administration of vildagliptin in radiation-induced POF. Methods: Female Sprague-dawley rats were randomly divided into four groups: control, radiation, radiation + vilda, or vilda alone groups. Vilda was administered orally once/day, and on the 10th day of the experiment, radiation and radiation + vilda group rats were subjected to 3.2 Gy of whole-body gamma irradiation. Behavioral activity was assessed on the 13th day of the experiment. On day 14 of the experiment, all rats were euthanized. Serum samples were collected, and ovaries were dissected for histological and biochemical analyses. Results: Irradiation of female rats resulted in increased locomotor hyperactivity, impaired memory, and ovarian damage as evidenced by the marked histopathological deterioration. Additionally, irradiation led to a significant decrease in body weight gain, gonadosomatic index, and serum estradiol level. Further, it caused a significant increase in serum AMH, phosphorylated AMPK, phosphorylated AKT, cytoplasmic Nrf2 expression and phosphorylated CREB levels. Co-administration of vilda exhibited neuroprotective effects, preserved the ovarian histological architecture but failed to preserve the primordial follicle pool in irradiated rats. Conclusion: In conclusion, AMPK/AKT signaling pathway is upregulated in radiation-induced POF. It possibly contributes to POF pathogenesis by accelerating the activation of primordial follicles, hence leading to their premature depletion. Coadministration of vilda can protect the ovaries and temporarily preserve its endocrine function; however, it does not sustain the ovarian reproductive capacity due to the early depletion of the pool of primordial follicles. Women undergoing radiotherapy should be cautious with the use of AKT-activating drugs.
- Open Access
- 24 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
The antifibrotic effect of Vildagliptin and Diaminodiphenyl Sulfone in murine schistosomiasis mansoni
Schistosomiasis drastically affects human health, where S. mansoni-induced hepatic fibrosis remains a serious problem with no available drug yet. The current study aimed to evaluate the hepatoprotective effects of Vildagliptin (Vilda), Diaminodiphenyl Sulfone (DDS), and their combination (Vilda/DDS) against S. mansoni-induced hepatic fibrosis and elucidate their underlying molecular mechanisms. S.mansoni-infected mice were administered praziquantel (PZQ) for two consecutive days, or Vilda, DDS, and Vilda/DDS for 14 consecutive days. Schistosomiasis-induced hepatic fibrosis was assessed parasitologically, biochemically, and pathologically. Results revealed that Vilda, DDS, and Vida/DDS treatments significantly reduced worm count, oogram stages, ova count, and ameliorated the granulomatous inflammatory reactions and hepatotoxicity indices. Moreover, they enhanced hepatic Nrf2/HO-1 pathway with significant increasing SOD and reducing MDA levels. Furthermore, they significantly downregulated the hepatic TLR4/NF-κB and NLRP3 inflammasome pathways leading to a significant reduction in TNF-α and caspase-1 levels which is important in the activation of IL-1β and caspase-3. Notably, significant downregulation in hepatic TGF-β1, α-SMA, and MMP-9 expressions were also recorded. In conclusion, Vilda/DDS showed antioxidant, anti-inflammatory and antifibrotic activities in comparison to either Vilda or DDS alone against S. mansoni-induced hepatic fibrosis. Therefore, Vilda/DDS is a promising approach for managing S. mansoni infection, liver fibrosis, and associated disease morbidity.
- 24 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessThe antifibrotic effect of Vildagliptin and Diaminodiphenyl Sulfone in murine schistosomiasis mansoni
Schistosomiasis drastically affects human health, where S. mansoni-induced hepatic fibrosis remains a serious problem with no available drug yet. The current study aimed to evaluate the hepatoprotective effects of Vildagliptin (Vilda), Diaminodiphenyl Sulfone (DDS), and their combination (Vilda/DDS) against S. mansoni-induced hepatic fibrosis and elucidate their underlying molecular mechanisms. S.mansoni-infected mice were administered praziquantel (PZQ) for two consecutive days, or Vilda, DDS, and Vilda/DDS for 14 consecutive days. Schistosomiasis-induced hepatic fibrosis was assessed parasitologically, biochemically, and pathologically. Results revealed that Vilda, DDS, and Vida/DDS treatments significantly reduced worm count, oogram stages, ova count, and ameliorated the granulomatous inflammatory reactions and hepatotoxicity indices. Moreover, they enhanced hepatic Nrf2/HO-1 pathway with significant increasing SOD and reducing MDA levels. Furthermore, they significantly downregulated the hepatic TLR4/NF-κB and NLRP3 inflammasome pathways leading to a significant reduction in TNF-α and caspase-1 levels which is important in the activation of IL-1β and caspase-3. Notably, significant downregulation in hepatic TGF-β1, α-SMA, and MMP-9 expressions were also recorded. In conclusion, Vilda/DDS showed antioxidant, anti-inflammatory and antifibrotic activities in comparison to either Vilda or DDS alone against S. mansoni-induced hepatic fibrosis. Therefore, Vilda/DDS is a promising approach for managing S. mansoni infection, liver fibrosis, and associated disease morbidity.
- Open Access
- 15 January 2025
- Published by Springer Nature in Psychopharmacology
- Vol. 242 (3) , 563-578
Captopril attenuates oxidative stress and neuroinflammation implicated in cisplatin-induced cognitive deficits in rats
Rationale: One of the most debilitating drawbacks of cisplatin chemotherapy is neurotoxicity which elicits memory impairment and cognitive dysfunction (chemobrain). This is primarily triggered by oxidative stress and inflammation. Captopril, an angiotensin-converting enzyme inhibitor, has been reported as a neuroprotective agent owing to its antioxidant and anti-inflammatory effects. Objective: We examined the possible neuroprotective effect of captopril against cisplatin-induced neurological and behavioral abnormalities in rats. Methods: Chemobrain was induced in rats by cisplatin (5 mg/kg, i.p.) on the 7th and 14th days of the study while captopril was administered orally (25 mg/kg) daily for three weeks. The effects of captopril were assessed by performing behavioral tests, histological examination, and evaluation of oxidative stress and inflammatory markers. Results: Cisplatin caused learning/memory dysfunction assessed by passive avoidance and Y-maze tests, decline in locomotion, and rotarod motor balance loss which were further verified by neurodegeneration observed in histological examination. Also, cisplatin aggravated oxidative stress by elevating lipid peroxidation (MDA) levels and diminishing catalase activity. Moreover, cisplatin upregulated the neuroinflammatory markers (TNF, IL-6, GFAP, and NF-κB). Captopril successfully ameliorated cisplatin damage on the levels of neurobehavioral and histopathological changes. Mechanistically, captopril significantly diminished MDA production and preserved catalase antioxidant activity. Captopril also counteracted neuroinflammation through inhibiting NF-κB and its downstream proinflammatory cytokines besides repressing astrocyte activity by reducing GFAP expression. Conclusion: Our findings revealed that captopril could abrogate cisplatin neurotoxicity via reducing oxidative stress and neuroinflammation thus enhancing cognitive and behavioral performance. This could suggest the repurposing of captopril as a neuroprotective agent, especially in hypertensive cancer patients receiving cisplatin.
- 15 January 2025
- Published by Springer Nature in Psychopharmacology
- Vol. 242 (3) , 563-578
Open AccessCaptopril attenuates oxidative stress and neuroinflammation implicated in cisplatin-induced cognitive deficits in rats
Rationale: One of the most debilitating drawbacks of cisplatin chemotherapy is neurotoxicity which elicits memory impairment and cognitive dysfunction (chemobrain). This is primarily triggered by oxidative stress and inflammation. Captopril, an angiotensin-converting enzyme inhibitor, has been reported as a neuroprotective agent owing to its antioxidant and anti-inflammatory effects. Objective: We examined the possible neuroprotective effect of captopril against cisplatin-induced neurological and behavioral abnormalities in rats. Methods: Chemobrain was induced in rats by cisplatin (5 mg/kg, i.p.) on the 7th and 14th days of the study while captopril was administered orally (25 mg/kg) daily for three weeks. The effects of captopril were assessed by performing behavioral tests, histological examination, and evaluation of oxidative stress and inflammatory markers. Results: Cisplatin caused learning/memory dysfunction assessed by passive avoidance and Y-maze tests, decline in locomotion, and rotarod motor balance loss which were further verified by neurodegeneration observed in histological examination. Also, cisplatin aggravated oxidative stress by elevating lipid peroxidation (MDA) levels and diminishing catalase activity. Moreover, cisplatin upregulated the neuroinflammatory markers (TNF, IL-6, GFAP, and NF-κB). Captopril successfully ameliorated cisplatin damage on the levels of neurobehavioral and histopathological changes. Mechanistically, captopril significantly diminished MDA production and preserved catalase antioxidant activity. Captopril also counteracted neuroinflammation through inhibiting NF-κB and its downstream proinflammatory cytokines besides repressing astrocyte activity by reducing GFAP expression. Conclusion: Our findings revealed that captopril could abrogate cisplatin neurotoxicity via reducing oxidative stress and neuroinflammation thus enhancing cognitive and behavioral performance. This could suggest the repurposing of captopril as a neuroprotective agent, especially in hypertensive cancer patients receiving cisplatin.
- 8 June 2024
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 489, 116994
Neuroprotective effects of saxagliptin against radiation-induced cognitive impairment: Insights on Akt/CREB/SIRT1/BDNF signaling pathway
- 8 June 2024
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 489, 116994
Neuroprotective effects of saxagliptin against radiation-induced cognitive impairment: Insights on Akt/CREB/SIRT1/BDNF signaling pathway
- 8 June 2024
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 76 (8) , 1051-1064
Effect of carvedilol on pharmacokinetics of sofosbuvir and its metabolite GS-331007: role of P-glycoprotein
Sofosbuvir (SOF) is a P-glycoprotein (P-gp) substrate, and carvedilol (CAR) is an inhibitor of P-gp, suggesting that it may affect the oral pharmacokinetics and safety of SOF. The current study investigated the pharmacokinetic interaction of CAR with SOF and its metabolite, GS-331007, and the possible consequent toxicities in rats. To assess the pharmacokinetics of SOF and GS-331007, rats were divided into three groups; all received a single oral dose of SOF preceded with saline (SAL), verapamil (VER) as a standard P-gp inhibitor, or CAR, respectively. The serosal, plasma, and hepatic tissue contents of SOF and GS-331007 were assessed using LC-MS/MS. Renal and hepatic toxicities were assessed using biochemical and histopathological tests. Serosal and plasma concentrations of SOF and GS-331007 were increased in the presence of CAR, suggesting a significant inhibitory effect of CAR on intestinal P-gp. Simultaneously, the pharmacokinetic profile of SOF showed a significant increase in the Cmax, AUC(0-t), AUC (0-∞), t1/2, and a reduction in its apparent oral clearance. While the pharmacokinetic profile of GS-331007 was not significantly affected. However, this notable elevation in drug oral bioavailability was corroborated by a significant alteration in renal functions. Hence, further clinical investigations are recommended to ensure the safety and dosing of CAR/SOF combination.
- 8 June 2024
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 76 (8) , 1051-1064
Effect of carvedilol on pharmacokinetics of sofosbuvir and its metabolite GS-331007: role of P-glycoprotein
Sofosbuvir (SOF) is a P-glycoprotein (P-gp) substrate, and carvedilol (CAR) is an inhibitor of P-gp, suggesting that it may affect the oral pharmacokinetics and safety of SOF. The current study investigated the pharmacokinetic interaction of CAR with SOF and its metabolite, GS-331007, and the possible consequent toxicities in rats. To assess the pharmacokinetics of SOF and GS-331007, rats were divided into three groups; all received a single oral dose of SOF preceded with saline (SAL), verapamil (VER) as a standard P-gp inhibitor, or CAR, respectively. The serosal, plasma, and hepatic tissue contents of SOF and GS-331007 were assessed using LC-MS/MS. Renal and hepatic toxicities were assessed using biochemical and histopathological tests. Serosal and plasma concentrations of SOF and GS-331007 were increased in the presence of CAR, suggesting a significant inhibitory effect of CAR on intestinal P-gp. Simultaneously, the pharmacokinetic profile of SOF showed a significant increase in the Cmax, AUC(0-t), AUC (0-∞), t1/2, and a reduction in its apparent oral clearance. While the pharmacokinetic profile of GS-331007 was not significantly affected. However, this notable elevation in drug oral bioavailability was corroborated by a significant alteration in renal functions. Hence, further clinical investigations are recommended to ensure the safety and dosing of CAR/SOF combination.
- 2 March 2024
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 485, 116875
Ondansetron attenuates cisplatin-induced behavioral and cognitive impairment through downregulation of NOD-like receptor inflammasome pathway
- 2 March 2024
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 485, 116875
Ondansetron attenuates cisplatin-induced behavioral and cognitive impairment through downregulation of NOD-like receptor inflammasome pathway